Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-12-03T19:24:21.496Z Has data issue: false hasContentIssue false
  • English
  • Français

Premorbid cannabis use is associated with more symptoms and poorer functioning in schizophrenia spectrum disorder

Published online by Cambridge University Press:  18 August 2016

P. A. Ringen ,
R. Nesvåg ,
S. Helle ,
T. V. Lagerberg ,
E. H. Lange ,
E. M. Løberg ,
I. Agartz ,
O. A. Andreassen  and
I. Melle
P. A. Ringen*
Affiliation:
Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway NORMENT, K. G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
R. Nesvåg
Affiliation:
Department of mental disorders, Norwegian Institute of Public Health, Oslo, Norway Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway
S. Helle
Affiliation:
Division of Psychiatry, Haukeland University Hospital, Bergen, Norway
T. V. Lagerberg
Affiliation:
Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway NORMENT, K. G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
E. H. Lange
Affiliation:
NORMENT, K. G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway
E. M. Løberg
Affiliation:
Division of Psychiatry, Haukeland University Hospital, Bergen, Norway Department of Clinical Psychology, University of Bergen, Bergen, Norway
I. Agartz
Affiliation:
Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway Department of Psychiatry, Diakonhjemmet Hospital, Oslo, Norway
O. A. Andreassen
Affiliation:
Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway NORMENT, K. G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
I. Melle
Affiliation:
Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway NORMENT, K. G. Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
*
*Address for correspondence: Dr P. A. Ringen, Division of Mental Health and Addiction, Oslo University Hospital HF, Psychosis Research Unit/TOP, Ullevål Hospital, Building 49, P.O. Box 4956 Nydalen, N-0424, Oslo, Norway. (Email: [email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Cannabis use disorder is associated with an earlier age at onset and a more severe outcome of schizophrenia spectrum disorders. The role of cannabis use before the onset of illness (premorbid cannabis use) has not been fully investigated. We here examined how amount and type of premorbid cannabis use was associated with the later course of illness including current substance use, symptoms and level of functioning in schizophrenia spectrum disorder.

Method

We used a naturalistic sample of patients with DSM-IV schizophrenia spectrum disorders with a comprehensive history of illness and substance use. Data on premorbid substance use was obtained from comprehensive self-report. The relationship to outcome was investigated using regression models that included current substance use and premorbid functioning.

Results

Pre-schizophrenia cannabis use was significantly associated with more severe psychotic symptoms and impaired functioning. Higher levels of premorbid cannabis use were associated with higher levels of current psychotic symptoms. These associations were independent of current substance use and premorbid functioning. Early use of cannabis (age <17 years) was associated with earlier age at onset of psychosis, independently of potential confounders.

Conclusions

Pre-psychosis cannabis use affects illness outcome in schizophrenia spectrum disorders, and is associated with lower age at onset of psychosis. These findings of independent negative effects of premorbid cannabis use in schizophrenia suggest that a limitation of the general use of cannabis may have beneficial health effects.

Keywords

Age at onsetcannabispremorbidpsychosisschizophrenia
Type
Original Articles
Information
Psychological Medicine , Volume 46 , Issue 15 , November 2016 , pp. 3127 - 3136
Copyright
Copyright © Cambridge University Press 2016 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Addington, D, Addington, J, Schissel, B (1990). A depression rating scale for schizophrenics. Schizophrenia Research 3, 247–251.Google Scholar
Albert, N, Bertelsen, M, Thorup, A, Petersen, L, Jeppesen, P, Le Quack, P, Krarup, G, Jørgensen, P, Nordentoft, M (2011). Predictors of recovery from psychosis, Analyses of clinical and social factors associated with recovery among patients with first-episode psychosis after 5 years. Schizophrenia Research 125, 257–266.Google Scholar
Alpar, A, Di Marzo, V, Harkany, T (2015). At the tip of an iceberg, prenatal marijuana and its possible relation to neuropsychiatric outcome in the offspring. Biological Psychiatry 79, e33–45.Google Scholar
Arndt, S, Tyrrell, G, Flaum, M, Andreasen, NC (1992). Comorbidity of substance abuse and schizophrenia, the role of pre-morbid adjustment. Psychological Medicine 22, 379–388.CrossRefGoogle ScholarPubMed
Auther, AM, McLaughlin, D, Carrion, RE, Nagachandran, P, Correll, CU, Cornblatt, BA (2012). Prospective study of cannabis use in adolescents at clinical high risk for psychosis, impact on conversion to psychosis and functional outcome. Psychological Medicine 42, 2485–2497.CrossRefGoogle ScholarPubMed
Barrowclough, C, Emsley, R, Eisner, E, Beardmore, R, Wykes, T (2013). Does change in cannabis use in established psychosis affect clinical outcome? Schizophrenia Bulletin 39, 339–348.Google Scholar
Barrowclough, C, Gregg, L, Lobban, F, Bucci, S, Emsley, R (2015). The impact of cannabis use on clinical outcomes in recent onset psychosis. Schizophrenia Bulletin 41, 382–390.Google Scholar
Brill, N, Levine, SZ, Reichenberg, A, Lubin, G, Weiser, M, Rabinowitz, J (2009). Pathways to functional outcomes in schizophrenia, the role of premorbid functioning, negative symptoms and intelligence. Schizophrenia Research 110, 40–46.Google Scholar
Brill, N, Reichenberg, A, Rabinowitz, J, Harary, E, Lubin, G, Davidson, M, Weiser, M (2007). Accuracy of self-reported premorbid functioning in schizophrenia. Schizophrenia Research 97, 103–108.CrossRefGoogle ScholarPubMed
Cannon-Spoor, HE, Potkin, SG, Wyatt, RJ (1982). Measurement of premorbid adjustment in chronic schizophrenia. Schizophrenia Bulletin 8, 470–484.Google Scholar
Compton, MT, Broussard, B, Ramsay, CE, Stewart, T (2011). Pre-illness cannabis use and the early course of nonaffective psychotic disorders, associations with premorbid functioning, the prodrome, and mode of onset of psychosis. Schizophrenia Research 126, 71–76.Google Scholar
D'Souza, DC, Abi-Saab, WM, Madonick, S, Forselius-Bielen, K, Doersch, A, Braley, G, Gueorguieva, R, Cooper, TB, Krystal, JH (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia, implications for cognition, psychosis, and addiction. Biological Psychiatry 57, 594–608.Google Scholar
Davis, GP, Compton, MT, Wang, S, Levin, FR, Blanco, C (2013). Association between cannabis use, psychosis, and schizotypal personality disorder, findings from the National Epidemiologic Survey of Alcohol and Related Conditions. Schizophrenia Research 151, 197–202.CrossRefGoogle Scholar
Dekker, N, Meijer, J, Koeter, M, Van den Brink, W, Van Beveren, N, Kahn, RS, Linszen, DH, Van Os, J, Wiersma, D, Bruggeman, R, Cahn, W, De Haan, L, Krabbendam, L, Myin-Germeys, I (2012). Age at onset of non-affective psychosis in relation to cannabis use, other drug use and gender. Psychological Medicine 42, 1903–1911.Google Scholar
DeRosse, P, Kaplan, A, Burdick, KE, Lencz, T, Malhotra, AK (2010). Cannabis use disorders in schizophrenia, effects on cognition and symptoms. Schizophrenia Research 120, 95–100.CrossRefGoogle ScholarPubMed
Di Forti, M, Sallis, H, Allegri, F, Trotta, A, Ferraro, L, Stilo, SA, Marconi, A, La Cascia, C, Reis Marques, T, Pariante, C, Dazzan, P, Mondelli, V, Paparelli, A, Kolliakou, A, Prata, D, Gaughran, F, David, AS, Morgan, C, Stahl, D, Khondoker, M, MacCabe, JH, Murray, RM (2014). Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophrenia Bulletin 40, 1509–1517.CrossRefGoogle ScholarPubMed
Filbey, FM, McQueeny, T, DeWitt, SJ, Mishra, V (2015). Preliminary findings demonstrating latent effects of early adolescent marijuana use onset on cortical architecture. Developmental Cognitive Neuroscience 16, 16–22.Google Scholar
French, L, Gray, C, Leonard, G, Perron, M, Pike, GB, Richer, L, Seguin, JR, Veillette, S, Evans, CJ, Artiges, E, Banaschewski, T, Bokde, AW, Bromberg, U, Bruehl, R, Buchel, C, Cattrell, A, Conrod, PJ, Flor, H, Frouin, V, Gallinat, J, Garavan, H, Gowland, P, Heinz, A, Lemaitre, H, Martinot, JL, Nees, F, Orfanos, DP, Pangelinan, MM, Poustka, L, Rietschel, M, Smolka, MN, Walter, H, Whelan, R, Timpson, NJ, Schumann, G, Smith, GD, Pausova, Z, Paus, T (2015). Early cannabis use, polygenic risk score for schizophrenia and brain maturation in adolescence. JAMA Psychiatry 72, 1002–1011.CrossRefGoogle ScholarPubMed
Green, AI, Drake, RE, Brunette, MF, Noordsy, DL (2007). Schizophrenia and co-occurring substance use disorder. American Journal of Psychiatry 164, 402–408.Google Scholar
Griffith-Lendering, MFH, Wigman, JTW, Prince van Leeuwen, A, Huijbregts, SCJ, Huizink, AC, Ormel, J, Verhulst, FC, Van Os, J, Swaab, H, Vollebergh, WAM (2013). Cannabis use and vulnerability for psychosis in early adolescence – a TRAILS study. Addiction 108, 733–740.CrossRefGoogle ScholarPubMed
Hartz, SM, Pato, CN, Medeiros, H, Cavazos-Rehg, P, Sobell, JL, Knowles, JA, Bierut, LJ, Pato, MT (2014). Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry 71, 248–254.CrossRefGoogle ScholarPubMed
Jockers-Scherubl, MC, Wolf, T, Radzei, N, Schlattmann, P, Rentzsch, J, De Gomez-Carrillo, CA, Kuhl, KP (2007). Cannabis induces different cognitive changes in schizophrenic patients and in healthy controls. Progress in Neuropsychopharmacology and Biological Psychiatry 31, 1054–1063.Google Scholar
Kay, SR, Fiszbein, A, Opler, LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261–276.Google Scholar
Khantzian, EJ (1985). The self-medication hypothesis of addictive disorders, focus on heroin and cocaine dependence. American Journal of Psychiatry 142, 1259–1264.Google Scholar
Kolliakou, A, Joseph, C, Ismail, K, Atakan, Z, Murray, RM (2011). Why do patients with psychosis use cannabis and are they ready to change their use? International Journal of Developmental Neuroscience 29, 335–346.CrossRefGoogle ScholarPubMed
Lambert, M, Conus, P, Lubman, DI, Wade, D, Yuen, H, Moritz, S, Naber, D, McGorry, PD, Schimmelmann, DG (2005). The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatrica Scandinavica 112, 141–148.CrossRefGoogle ScholarPubMed
Large, M, Di Forti, M, Murray, RM (2015). Cannabis, debated schizophrenia link. Nature 527(7578), 305.CrossRefGoogle ScholarPubMed
Large, M, Mullin, K, Gupta, P, Harris, A, Nielssen, O (2014). Systematic meta-analysis of outcomes associated with psychosis and co-morbid substance use. Australia and New Zealand Journal of Psychiatry 48, 418–432.CrossRefGoogle ScholarPubMed
Larsen, TK, Friis, S, Haahr, U, Johannessen, JO, Melle, I, Opjordsmoen, S, Rund, BR, Simonsen, E, Vaglum, P, McGlashan, TH (2004). Premorbid adjustment in first-episode non-affective psychosis, distinct patterns of pre-onset course. British Journal of Psychiatry 185, 108–115.Google Scholar
Linszen, DH, Dingemans, PM, Lenior, ME (1994). Cannabis abuse and the course of recent-onset schizophrenic P. M. disorders. Archives of General Psychiatry 51, 273–279.Google Scholar
Lopez-Larson, MP, Bogorodzki, P, Rogowska, J, McGlade, E, King, JB, Terry, J, Yurgelun-Todd, D (2011). Altered prefrontal and insular cortical thickness in adolescent marijuana users. Behavioral Brain Research 220, 164–172.CrossRefGoogle ScholarPubMed
Malone, DT, Hill, MN, Rubino, T (2010). Adolescent cannabis use and psychosis, epidemiology and neurodevelopmental models. British Journal of Pharmacology 160, 511–522.Google Scholar
Manrique-Garcia, E, Zammit, S, Dalman, C, Hemmingsson, T, Andreasson, S, Allebeck, P (2014). Prognosis of schizophrenia in persons with and without a history of cannabis use. Psychological Medicine 44, 2513–2521.Google Scholar
Margolese, HC, Malchy, L, Negrete, JC, Tempier, R, Gill, K (2004). Drug and alcohol use among patients with schizophrenia and related psychoses, levels and consequences. Schizophrenia Research 67, 157–166.Google Scholar
McGrath, J, Welham, J, Scott, J, Varghese, D, Degenhardt, L, Hayatbakhsh, MR, Alati, R, Williams, GM, Bor, W, Najman, JM (2010). Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Archives of General Psychiatry 67, 440–447.CrossRefGoogle Scholar
McKetin, R, Lubman, DI, Baker, AL, Dawe, S, Ali, RL (2013). Dose-related psychotic symptoms in chronic methamphetamine users, evidence from a prospective longitudinal study. JAMA Psychiatry 70, 319–324.Google Scholar
Miettunen, J, Törmänen, S, Murray, GK, Jones, PB, Mäki, P, Ebeling, H, Moilanen, I, Taanila, A, Heinimaa, M, Joukamaa, M, Veijola, J (2008). Association of cannabis use with prodromal symptoms of psychosis in adolescence. British Journal of Psychiatry 192, 470–1.Google Scholar
Moore, TH, Zammit, S, Lingford-Hughes, A, Barnes, TR, Jones, PB, Burke, M, Lewis, G (2007). Cannabis use and risk of psychotic or affective mental health outcomes, a systematic review. Lancet 370(9584), 319–328.Google Scholar
National Institute of Health (2016). Adolescent Brain Cognitive Development Study (http://addictionresearch.nih.gov/adolescent-brain-cognitive-development-study). Accessed 18 January 2016.Google Scholar
Niemi-Pynttari, JA, Sund, R, Putkonen, H, Vorma, H, Wahlbeck, K, Pirkola, SP (2013). Substance-induced psychoses converting into schizophrenia, a register-based study of 18 478 Finnish inpatient cases. Journal of Clinical Psychiatry 74, e94–e99.Google Scholar
Pedersen, G, Hagtvet, KA, Karterud, S (2007). Generalizability studies of the Global Assessment of Functioning-Split version. Comprehensive Psychiatry 48, 88–94.Google Scholar
Potvin, S, Joyal, S, Pelletier, P, and Stip, E (2008). Contradictory cognitive capacities among substance-abusing patients with schizophrenia, A meta-analysis. Schizophrenia Research 100, 242–251.Google Scholar
Power, BD, Stefanis, NC, Dragovic, M, Jablensky, A, Castle, D, Morgan, V (2014). Age at initiation of amphetamine use and age at onset of psychosis, the Australian Survey of High Impact Psychosis. Schizophrenia Research 152, 300–302.Google Scholar
Ringen, PA, Lagerberg, TV, Birkenaes, AB, Engh, JA, Faerden, A, Jonsdottir, H, Nesvag, R, Friis, S, Opjordsmoen, S, Larsen, F, Melle, I, Andreassen, OA (2007). Differences in prevalence and patterns of substance use in schizophrenia and bipolar disorder. Psychological Medicine 38, 1241–1249.Google Scholar
Ringen, PA, Melle, I, Birkenaes, AB, Engh, JA, Faerden, A, Vaskinn, A, Friis, S, Opjordsmoen, S, Andreassen, OA (2008). The level of illicit drug use is related to symptoms and premorbid functioning in severe mental illness. Acta Psychiatrica Scandinavica 118, 297–304.Google Scholar
Ruiz-Veguilla, M, Barrigón, ML, Hernández, L, Rubio, JL, Gurpegui, M, Sarramea, F, Cervilla, J, Gutiérrez, B, James, A, Ferrin, M (2013). Dose–response effect between cannabis use and psychosis liability in a non-clinical population, Evidence from a snowball sample. Journal of Psychiatric Research 47, 1036–1043.Google Scholar
Shrout, PE, Fleiss, JL (1979). Intraclass correlations, uses in assessing rater reliability. Psychological Bulletin 86, 420–428.CrossRefGoogle ScholarPubMed
Stefanis, NC, Dragovic, M, Power, BD, Jablensky, A, Castle, D, Morgan, VA (2014). The effect of drug use on the age at onset of psychotic disorders in an Australian cohort. Schizophrenia Research 156, 211–216.CrossRefGoogle Scholar
Stone, JM, Fisher, HL, Major, B, Chisholm, B, Woolley, J, Lawrence, J, Rahaman, N, Joyce, J, Hinton, M, Johnson, S, Young, AH (2014). Cannabis use and first-episode psychosis, relationship with manic and psychotic symptoms, and with age at presentation. Psychological Medicine 44, 499–506.Google Scholar
Talamo, A, Centorrino, F, Tondo, L, Dimitri, A, Hennen, J, Baldessarini, RJ (2006). Comorbid substance-use in schizophrenia, relation to positive and negative symptoms. Schizophrenia Research 86, 251–255.Google Scholar
Tosato, SA, Lasalvia, A, Bonetto, C, Mazzoncini, R, Cristofalo, D, De Santi, K, Bertani, M, Bissoli, S, Lazzarotto, L, Marrella, G, Lamonaca, D, Riolo, R, Gardellini, F, Urbani, A, Tansella, M, Ruggeri, M (2013). The impact of cannabis use on age of onset and clinical characteristics in first-episode psychotic patients. Data from the Psychosis Incident Cohort Outcome Study (PICOS). Journal of Psychiatric Research 47, 438–444.Google Scholar
Valmaggia, LR, Day, FL, Jones, C, Bissoli, S, Pugh, C, Hall, D, Bhattacharyya, S, Howes, O, Stone, J, Fusar-Poli, P, Byrne, M, McGuire, PK (2014). Cannabis use and transition to psychosis in people at ultra-high risk. Psychological Medicine 44, 2503–2512.Google Scholar
Van Dorn, RA, Desmarais, SL, Scott Young, M, Sellers, BG, Swartz, MS (2012). Assessing illicit drug use among adults with schizophrenia. Psychiatry Research 200, 228–236.CrossRefGoogle ScholarPubMed
Van Gastel, WA, Vreeker, A, Schubart, CD, Maccabe, JH, Kahn, RS, Boks, MP (2014). Change in cannabis use in the general population, a longitudinal study on the impact on psychotic experiences. Schizophrenia Research 157, 266–270.Google Scholar
Ventura, JJ, Liberman, RP, Green, MF, Shaner, A, Mintz, J (1998). Training and quality assurance with the Structured Clinical Interview for DSM-IV (SCID-I/P). Psychiatry Research 79, 163–173.CrossRefGoogle ScholarPubMed
Weiss, RD, Najavits, LM, Greenfield, SF, Soto, JA, Shaw, SR, Wyner, D (1998). Validity of substance use self-reports in dually diagnosed outpatients. American Journal of Psychiatry 155, 127–128.Google Scholar
Zammit, S, Moore, TH, Lingford-Hughes, A, Barnes, TR, Jones, PB, Burke, M, Lewis, G (2008). Effects of cannabis use on outcomes of psychotic disorders, systematic review. British Journal of Psychiatry 193, 357–363.Google Scholar